KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) FCF Margin (2016 - 2024)

Palvella Therapeutics has reported FCF Margin over the past 9 years, most recently at 3415.5% for Q3 2022.

  • Quarterly FCF Margin fell 306483.0% to 3415.5% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 300.94% through Sep 2022, down 25194.0% year-over-year, with the annual reading at 27.4% for FY2021, 17594.0% up from the prior year.
  • FCF Margin was 3415.5% for Q3 2022 at Palvella Therapeutics, up from 7046.52% in the prior quarter.
  • Over five years, FCF Margin peaked at 903.41% in Q2 2021 and troughed at 7046.52% in Q2 2022.
  • The 5-year median for FCF Margin is 178.22% (2019), against an average of 711.04%.
  • Year-over-year, FCF Margin soared 151611bps in 2019 and then plummeted -794993bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 1603.83% in 2018, then skyrocketed by 95bps to 87.72% in 2019, then tumbled by -951bps to 921.94% in 2020, then surged by 85bps to 140.86% in 2021, then plummeted by -2325bps to 3415.5% in 2022.
  • Per Business Quant, the three most recent readings for PVLA's FCF Margin are 3415.5% (Q3 2022), 7046.52% (Q2 2022), and 209.61% (Q1 2022).